Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 3/20 | 0.31 |
| ▸ | RAB9A | P51151 | 3/20 | 0.31 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.31 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.31 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.31 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714669 | 0.90 | HPGDS (0.38) | KMT2AMCHR1L3MBTL1SCN9ANPC1 | |
| SCHEMBL30714744 | 0.90 | HPGDS (0.38) | KMT2AMCHR1L3MBTL1SCN9ANPC1 | |
| SCHEMBL30714634 | 0.87 | KMT2A (0.34) | KMT2AMCHR1L3MBTL1SCN9ANPC1 | |
| SCHEMBL30714683 | 0.84 | NPC1 (0.34) | KMT2ASCN9ANPC1RAB9APOLB | |
| SCHEMBL30714617 | 0.83 | CYP11B2 (0.37) | KMT2AL3MBTL1SCN9ANPC1RAB9A | |
| SCHEMBL30714605 | 0.83 | KLKB1 (0.33) | KMT2AMCHR1SCN9ANPC1RAB9A | |
| SCHEMBL30714691 | 0.83 | KLKB1 (0.33) | KMT2AMCHR1SCN9ANPC1RAB9A | |
| SCHEMBL30714604 | 0.82 | MCHR1 (0.37) | KMT2AMCHR1L3MBTL1NPC1RAB9A | |
| SCHEMBL30714670 | 0.82 | MCHR1 (0.40) | KMT2AMCHR1L3MBTL1NPC1RAB9A | |
| SCHEMBL26874836 | 0.82 | MCHR1 (0.37) | KMT2AMCHR1L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| EP-4499624-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023230540-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM2, TRPV1 | KMT2A 3017/4885MCHR1 1891/4885L3MBTL1 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.